September 11, 2023-September 13, 2023 View Now: 2023 Rare and Orphan Disease Conference presented by C-Path Patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists will
August 10, 2023 View Now: Teaching Patients and Caregivers: The Role of Education in Research and Data Sharing Thursday, August 10, noon ET: This webinar will focus on the role of foundational education in research concepts, such as data lit
June 25, 2023-June 29, 2023 DIA 2023 Global Annual Meeting | ILLUMINATE The DIA 2023 Global Annual Meeting invites industry, regulatory government, academics, and patients to network, problem-solve, and
June 8, 2023 View Now: GUIDs and De-Identification Tools for Rare Diseases C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform is pleased to present this new webinar, GUIDs and De-Identi
April 27, 2023 View Now | Clinical Outcome Assessments: Does one size fit all? Join C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform and its Rare Disease Clinical Outcome Assessment
March 15, 2023 View Now | CP-RND: An Introduction to the Patient Community Hosted by the C-Path team, you can view this recorded webinar to learn more about the Critical Path for Rare Neurodegenerative Dis
December 14, 2022 View Now | Shared Stewardship in Collaborative Curation of Rare Disease Datasets Patient data is a key asset in understanding the progression of rare diseases and may it be provided in a variety of forms from a
October 29, 2022 View Now | The Role of Integrated Datasets in Addressing Rare Diseases Research Challenges Gaining knowledge on rare diseases is limited by the scarcity and dispersity of patient data. Sequencing technologies have greatly
September 13, 2022-September 14, 2022 View Now | 2022 RDCA-DAP Workshop, September 13-14 Since its launch in 2019, the Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP®) has established i
August 17, 2022 View Now | Addressing the Gaps in Clinical Trial Readiness for FSHD Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common myopathies affecting anywhere between 1:8,000 to 1:20,000